Tranzyme Inc

Integrated Laboratory Systems provides comprehensive research, testing and support services in the health and environmental science markets. Its scientists and technicians have experience and expertise in a wide range of health and environmental disciplines, including environmental sciences, clinical research, investigative toxicology, molecular and pathological research, and alternative methods and bio-information. Most recently, ILS has moved into the clinical research arena with the award of a major contract studying Anencephaly. ILS' research facilities are located in Research Triangle Park, N.C.; Athens, Ga.; Golden, Colo.; and Washington, D.C. Integrated Laboratory Systems was founded as a research laboratory in 1985 by Dr. Thomas K. Rao.

PharPoint Research Inc is a contract research organization (CRO) based in Durham, NC. With over 1,000 studies supported since 2007, PharPoint offers a client-centric approach to help innovative clients meet their clinical trial goals. Their services include clinical operations, project management, site feasibility study start-up, medical monitoring, clinical data management, biostatistics, medical writing, and more. PharPoint is known for their industry-best biometrics timelines, delivering study results over a month faster than the industry average, and their transparent, attentive, and accessible team. PharPoint's success stories and proven track record demonstrate their commitment to reducing challenges early in the trial process through strategic site selection, prioritizing data quality and cleaning, and providing custom programming without added costs. Their experienced team, extensive industry experience, and partnerships with EDC providers allow them to deliver quality results efficiently. Trusted by 180 companies, PharPoint is dedicated to supporting clients from pre-IND planning through regulatory approval, ultimately contributing to the improvement of global health.Generated from the website

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.